181 related articles for article (PubMed ID: 17971996)
21. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
Winski SL; Hargreaves RH; Butler J; Ross D
Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
[TBL] [Abstract][Full Text] [Related]
22. Studies of pyrrolo[1,2-alpha]benzimidazolequinone DT-diaphorase substrate activity, topoisomerase II inhibition activity, and DNA reductive alkylation.
Skibo EB; Gordon S; Bess L; Boruah R; Heileman MJ
J Med Chem; 1997 Apr; 40(9):1327-39. PubMed ID: 9135030
[TBL] [Abstract][Full Text] [Related]
23. Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes.
Chen S; Knox R; Lewis AD; Friedlos F; Workman P; Deng PS; Fung M; Ebenstein D; Wu K; Tsai TM
Mol Pharmacol; 1995 May; 47(5):934-9. PubMed ID: 7746280
[TBL] [Abstract][Full Text] [Related]
24. NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer.
Zhang K; Chen D; Ma K; Wu X; Hao H; Jiang S
J Med Chem; 2018 Aug; 61(16):6983-7003. PubMed ID: 29712428
[TBL] [Abstract][Full Text] [Related]
25. The role of NAD(P)H:quinone oxidoreductase in quinone-mediated p21 induction in human colon carcinoma cells.
Qiu XB; Cadenas E
Arch Biochem Biophys; 1997 Oct; 346(2):241-51. PubMed ID: 9343371
[TBL] [Abstract][Full Text] [Related]
26. Characterization of the quinone reductase activity of the ferric reductase B protein from Paracoccus denitrificans.
Sedlácek V; van Spanning RJ; Kucera I
Arch Biochem Biophys; 2009 Mar; 483(1):29-36. PubMed ID: 19138657
[TBL] [Abstract][Full Text] [Related]
27. An alternatively spliced form of NQO1 (DT-diaphorase) messenger RNA lacking the putative quinone substrate binding site is present in human normal and tumor tissues.
Gasdaska PY; Fisher H; Powis G
Cancer Res; 1995 Jun; 55(12):2542-7. PubMed ID: 7780966
[TBL] [Abstract][Full Text] [Related]
28. Evidence for NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated quinone-dependent redox cycling via plasma membrane electron transport: A sensitive cellular assay for NQO1.
Tan AS; Berridge MV
Free Radic Biol Med; 2010 Feb; 48(3):421-9. PubMed ID: 19932748
[TBL] [Abstract][Full Text] [Related]
29. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity.
Traver RD; Horikoshi T; Danenberg KD; Stadlbauer TH; Danenberg PV; Ross D; Gibson NW
Cancer Res; 1992 Feb; 52(4):797-802. PubMed ID: 1737339
[TBL] [Abstract][Full Text] [Related]
30. The synthesis of 2-nitroaryl-1,2,3,4-tetrahydroisoquinolines, nitro-substituted 5,6-dihydrobenzimidazo[2,1-a]isoquinoline N-oxides and related heterocycles as potential bioreducible substrates for the enzymes NAD(P)H: quinone oxidoreductase 1 and E. coli nitroreductase.
Burke PJ; Wong LC; Jenkins TC; Knox RJ; Stanforth SP
Bioorg Med Chem Lett; 2011 Dec; 21(24):7447-50. PubMed ID: 22074961
[TBL] [Abstract][Full Text] [Related]
31. Natural product-inspired profluorophores for imaging NQO1 activity in tumour tissues.
Cheng Z; Valença WO; Dias GG; Scott J; Barth ND; de Moliner F; Souza GBP; Mellanby RJ; Vendrell M; da Silva Júnior EN
Bioorg Med Chem; 2019 Sep; 27(17):3938-3946. PubMed ID: 31327676
[TBL] [Abstract][Full Text] [Related]
32. Structure and mechanism of NAD[P]H:quinone acceptor oxidoreductases (NQO).
Bianchet MA; Faig M; Amzel LM
Methods Enzymol; 2004; 382():144-74. PubMed ID: 15047101
[No Abstract] [Full Text] [Related]
33. Mitomycin C.
Gibson NW; Ross D
Cancer Chemother Biol Response Modif; 1993; 14():45-54. PubMed ID: 8312113
[TBL] [Abstract][Full Text] [Related]
34. Chemical synthesis and biological evaluation of a NAD(P)H:quinone oxidoreductase-1 targeted tripartite quinone drug delivery system.
Volpato M; Abou-Zeid N; Tanner RW; Glassbrook LT; Taylor J; Stratford I; Loadman PM; Jaffar M; Phillips RM
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3122-30. PubMed ID: 18089707
[TBL] [Abstract][Full Text] [Related]
35. Problematic detoxification of estrogen quinones by NAD(P)H-dependent quinone oxidoreductase and glutathione-S-transferase.
Chandrasena RE; Edirisinghe PD; Bolton JL; Thatcher GR
Chem Res Toxicol; 2008 Jul; 21(7):1324-9. PubMed ID: 18588320
[TBL] [Abstract][Full Text] [Related]
36. Evidence from ESI-MS for NQO1-catalyzed reduction of estrogen ortho-quinones.
Gaikwad NW; Rogan EG; Cavalieri EL
Free Radic Biol Med; 2007 Nov; 43(9):1289-98. PubMed ID: 17893042
[TBL] [Abstract][Full Text] [Related]
37. NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.
Jamieson D; Wilson K; Pridgeon S; Margetts JP; Edmondson RJ; Leung HY; Knox R; Boddy AV
Clin Cancer Res; 2007 Mar; 13(5):1584-90. PubMed ID: 17332305
[TBL] [Abstract][Full Text] [Related]
38. Kinetics of NAD(P)H:quinone oxidoreductase I (NQO1) inhibition by mitomycin C in vitro and in vivo.
Gustafson DL; Siegel D; Rastatter JC; Merz AL; Parpal JC; Kepa JK; Ross D; Long ME
J Pharmacol Exp Ther; 2003 Jun; 305(3):1079-86. PubMed ID: 12649308
[TBL] [Abstract][Full Text] [Related]
39. Combined molecular modelling and 3D-QSAR study for understanding the inhibition of NQO1 by heterocyclic quinone derivatives.
López-Lira C; Alzate-Morales JH; Paulino M; Mella-Raipán J; Salas CO; Tapia RA; Soto-Delgado J
Chem Biol Drug Des; 2018 Jan; 91(1):29-38. PubMed ID: 28643389
[TBL] [Abstract][Full Text] [Related]
40. Role of NAD(P)H:quinone oxidoreductase (NQO1) in apoptosis induction by aziridinylbenzoquinones RH1 and MeDZQ.
Nemeikaite-Ceniene A; Dringeliene A; Sarlauskas J; Cenas N
Acta Biochim Pol; 2005; 52(4):937-41. PubMed ID: 15940348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
